Trial Profile
A Single-center,Open-label Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary)
- Indications COVID 2019 infections; Respiratory tract infections
- Focus Adverse reactions; First in man
- Acronyms APICTH; CTCOVID-19
- Sponsors Tianjin CanSino Biotechnology
- 02 Aug 2021 Status changed from active, no longer recruiting to completed.
- 26 May 2020 Results published in the the Lancet
- 29 Mar 2020 Status changed from recruiting to active, no longer recruiting.